Public Health Law 1972, Section 3(3)(d): The Enforcement Basis in Myanmar

1. Key takeaways

The medical device field in Myanmar lacks a dedicated law, but enforcement does not therefore lose its legal basis. An authority that can be traced to a specific provision number comes from Sub-Section 3(d) of Section 3 of the Public Health Law 1972. The Myanmar state media Global New Light of Myanmar, in reporting the FDA’s announcement of 30 unregistered cosmetics containing prohibited chemical ingredients, expressly recorded that the competent authority would take legal action against non-compliant parties under this provision.

• This provision is a general public health authorisation, not a device-specific clause, so its scope of application is not limited to any particular product category.
• Precisely because it is a general authorisation, its coverage is broader than a dedicated law, and in a market without a dedicated statute companies find it harder, not easier, to argue that the law is silent.
• The provision has been cited directly in state media reporting on FDA enforcement announcements, confirming that it is actively used rather than dormant.
• The authorisation links to the ASEAN Post-Market Alert System (PMAS) and to systematic FDA market surveillance, so enforcement actions have a regional information source behind them.
• In the reported case, the FDA announcement targeted 30 unregistered cosmetics containing prohibited chemical ingredients, and the state media record tied the planned legal action expressly to this provision, which demonstrates the breadth of product categories it can reach.
• Because the provision sits in a 1972 public health statute rather than a device code, its language contains no device-specific exemptions or transition arrangements, and companies should not assume any of the defences available under dedicated device legislation.

2. Legal basis

The table below sets out the statutory anchor of enforcement in Myanmar, together with the connected instruments that show how the general public health authority operates alongside regional alert mechanisms and consumer protection legislation.

3. Expert insights

Insight 1: section 3(3)(d) provides a residual channel for enforcement. In the absence of a dedicated law, the competent authority invokes general public health provisions to deal with unregistered products. The legal effect is that non-registration itself constitutes a compliance defect, without any further argument needed.

Insight 2: a general authorisation is harder to defend against than a specific one. Dedicated statutes usually contain exemption, transition and tiering provisions on which companies can assert rights; the exception space under a general public health authorisation is narrower. The compliance flexibility companies face in Myanmar is lower than in markets that have completed dedicated legislation.

Insight 3: this authorisation operates in linkage with the ASEAN Post-Market Alert System. The Myanmar FDA conducts market surveillance on the basis of PMAS reports and issues announcements, so enforcement actions are supported by a regional information source. This means that similar announcements from other ASEAN countries may transmit to Myanmar. A vigilance notice issued in a neighbouring market can therefore become the factual trigger for a Myanmar enforcement action, even where the product concerned has never been marketed locally, and the announcement can name importers and retailers by name once the product has entered local distribution.

Insight 4: the targets of enforcement cover the whole chain of import, distribution, wholesale and retail. Official announcements expressly point to importers, distributors, wholesalers and retailers. Foreign manufacturers are not directly bound by such announcements, but once their local chain is interrupted, the commercial consequences are borne by the manufacturer.

Insight 5: enforcement under a general clause signals that companies must prepare documentation to the strictest practical interpretation. Where the specific review standard is unclear, preparing the dossier against the complete AMDD technical documentation requirements is a prudent way to reduce the risk of deficiency requests. This interpretation of the practical standard should be treated as a practical estimate pending verification against the FDA’s current review practice. The same caution applies to the connected Consumer Protection Law, which regulates advertising and promotion and can be invoked in parallel with public health enforcement where promotional claims are involved.

4. Practical recommendations

• Treat non-registered status as an unacceptable compliance state. Do not arrange commercial supply to Myanmar before the product completes registration.
• Build the dossier against the complete AMDD technical documentation requirements. Even where Class A products may be simplified, construct the full structure first.
• Establish a regional vigilance information monitoring mechanism. Track announcements on similar products in other ASEAN markets and anticipate actions Myanmar may take.
• Define compliance responsibilities clearly in local chain contracts. Agree in advance on the cooperation and remediation obligations of importers and distributors when an announcement is issued.
• Keep tracking the enforcement basis. Watch whether the Myanmar FDA issues more specific device enforcement rules.

5. Verification checklist

• □ Confirmed section 3(3)(d) of the Public Health Law 1972 as the anchor of enforcement authority
• □ Confirmed that the authorisation is a general public health authorisation not limited to a specific product category
• □ Confirmed that the provision has been cited directly by Myanmar state media in reporting FDA announcements
• □ Established a monitoring mechanism for vigilance announcements in other ASEAN markets
• □ Agreed compliance and remediation obligations in local chain contracts
• □ Built the dossier against the complete AMDD technical documentation requirements

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Myanmar. Our team prepares the technical dossier to ASEAN CSDT structure, manages submission and deficiency responses with the Myanmar FDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com